Annual report pursuant to Section 13 and 15(d)

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)

v3.3.1.900
QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)
 12 Months Ended
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data
Quarterly financial data for 2015 and 2014 was as follows:
 
 
Three Months Ended
2015
 
March 31,
 
June 30,
 
September 30,
 
December 31,
 
 
(In millions, except per share data)
Operating revenue
 
$
651.8

 
$
678.1

 
$
667.4

 
$
666.3

Operating income
 
$
154.2

 
$
188.5

 
$
174.3

 
$
176.9

Consolidated net income
 
$
89.6

 
$
112.5

 
$
119.7

 
$
113.0

Net income attributable to Equifax
 
$
88.3

 
$
111.0

 
$
117.9

 
$
111.9

Basic earnings per share*
 
 

 
 

 
 

 
 

Net income attributable to Equifax
 
$
0.74

 
$
0.94

 
$
1.00

 
$
0.94

Diluted earnings per share*
 
 

 
 

 
 

 
 

Net income attributable to Equifax
 
$
0.73

 
$
0.92

 
$
0.98

 
$
0.93

 
 
 
Three Months Ended
2014
 
March 31,
 
June 30,
 
September 30,
 
December 31,
 
 
(In millions, except per share data)
Operating revenue
 
$
584.5

 
$
613.9

 
$
613.4

 
$
624.6

Operating income
 
$
151.9

 
$
167.4

 
$
153.7

 
$
165.2

Consolidated net income
 
$
86.3

 
$
94.5

 
$
94.4

 
$
98.8

Net income attributable to Equifax
 
$
83.9

 
$
92.8

 
$
92.7

 
$
98.0

Basic earnings per share*
 
 

 
 

 
 

 
 

Net income attributable to Equifax
 
$
0.69

 
$
0.76

 
$
0.77

 
$
0.82

Diluted earnings per share*
 
 

 
 

 
 

 
 

Net income attributable to Equifax
 
$
0.67

 
$
0.75

 
$
0.75

 
$
0.80

* 
The sum of the quarterly EPS does not equal the annual EPS due to changes in the weighted-average shares between periods.
 
The comparability of our quarterly financial results during 2015 and 2014 was impacted by certain events, as follows:
 
•
During Q1 2015, we recorded a $20.7 million restructuring charge ($13.2 million, net of tax) all of which was recorded in selling, general and administrative expenses on our Consolidated Statements of Income. For additional information about our acquisitions, see Note 13 of the Notes to Consolidated Financial Statements.

•
During Q2 2015, we recorded a 46.0 million Brazilian Reais ($14.8 million) impairment of our investment in BVS. For additional information about our acquisitions, see Note 2 of the Notes to Consolidated Financial Statements.

•
During Q1 2014, we made two acquisitions, the TDX and Forseva, for a total of $338.8 million. For additional information about our acquisitions, see Note 4 of the Notes to Consolidated Financial Statements.